Baseline characteristics of CATCH patients with ERA (n = 1840). Values are number (%) unless otherwise indicated.
| Characteristic | Missing, n (%) | |
|---|---|---|
| Demographic | ||
| Age, mean ± SD yrs | 0 | 53.4 ± 15.3 |
| White | 0 | 1504 (81.7) |
| Female sex | 0 | 1342 (72.9) |
| Smoker, n = 1834 | 6 (0.3) | |
| Current | — | 337 (18.4) |
| Ex-smoker | — | 691 (37.7) |
| Never | — | 806 (43.9) |
| Clinical | ||
| Symptom duration, mos, mean ± SD | 6 (0.3) | 5.94 ± 3.53 |
| TJC in 28 joints, mean ± SD | 4 (0.2) | 8.80 ± 6.62 |
| SJC in 28 joints, mean ± SD | 4 (0.2) | 7.90 ± 6.07 |
| Duration AM stiffness, h, mean ± SD | 16 (0.9) | 0.62 ± 0.48 |
| VAS pain, mm, mean ± SD (0–100 mm scale) | 69 (3.8) | 56.17 ± 28.20 |
| VAS fatigue, mm, mean ± SD (0–100 mm scale) | 36 (1.9) | 53.13 ± 30.27 |
| PtGA, mm, mean ± SD (0–100 mm scale) | 36 (1.9) | 58.64 ± 29.22 |
| MDGA, mean ± SD mm (0–100 mm scale) | 34 (1.8) | 49.26 ± 24.37 |
| DAS28-ESR score, mean ± SD | 170 (9.2) | 5.09 ± 1.44 |
| SDAI score, mean ± SD | 226 (12.3) | 28.83 ± 14.80 |
| SDAI low disease status | 226 (12.3) | 162 (10) |
| M-HAQ score, mean ± SD | 53 (2.9) | 1.04 ± 0.71 |
| Presence of erosions ** | 342 (18.5) | 399 (26.6) |
| Laboratory | ||
| ESR, mm/h, mean ± SD | 133 (7.2) | 27.90 ± 23.18 |
| CRP, mg/l, mean ± SD | 164 (8.9) | 1.47 ± 1.82 |
| RF-positive ** | 186 (10.1) | 1038 (62.8) |
| ACPA-positive** | 584 (31.6) | 693 (55.2) |
| Initial treatment during first 3 mos | ||
| Combination therapy (MTX or LEF ± SSZ ± HCQ) | 109 (5.9) | 793 (45.8) |
| MTX alone | 109 (5.9) | 549 (31.7) |
| Oral corticosteroid (alone or with DMARD)* | 109 (5.9) | 537 (31.0) |
| No DMARD | 109 (5.9) | 162 (9.4) |
| Biologic agent | 109 (5.9) | 39 (2.3) |
↵* Ninety-three percent of oral corticosteroid was used with combination DMARD therapy.
↵** Data for RF, ACPA, and erosions are based on nonimputed data. CATCH: Canadian Early Arthritis Cohort; ERA: early rheumatoid arthritis; ACPA: anticitrullinated protein antibodies; CDAI: Clinical Disease Activity Index; CRP: C-reactive protein; DAS28-ESR: 28-joint Disease Activity Score using ESR; DMARD: disease-modifying antirheumatic drug; ESR: erythrocyte sedimentation rate; HCQ: hydroxychloroquine; LEF: leflunomide; MDGA: physician global assessment of disease; M-HAQ: modified Health Assessment Questionnaire; MTX: methotrexate; PtGA: patient global assessment of disease; RA: rheumatoid arthritis; RF: rheumatoid factor; SDAI: Simplified Disease Activity Index; SJC: swollen joint count; SSZ: sulfasalazine; TJC: tender joint count; VAS: visual analog scale.